113 related articles for article (PubMed ID: 8191401)
1. Antithrombotic effect of recombinant truncated tissue factor pathway inhibitor (TFPI1-161) in experimental venous thrombosis--a comparison with low molecular weight heparin.
Holst J; Lindblad B; Bergqvist D; Nordfang O; Ostergaard PB; Petersen JG; Nielsen G; Hedner U
Thromb Haemost; 1994 Feb; 71(2):214-9. PubMed ID: 8191401
[TBL] [Abstract][Full Text] [Related]
2. Does glycosylation influence the experimental antithrombotic effect of a two-domain tissue factor pathway inhibitor?
Holst J; Lindblad B; Nordfang O; Ostergaard PB; Hedner U
Haemostasis; 1996; 26(1):23-30. PubMed ID: 8698275
[TBL] [Abstract][Full Text] [Related]
3. Experimental haemorrhagic effect of two-domain non-glycosylated tissue factor pathway inhibitor compared to low molecular weight heparin.
Holst J; Lindblad B; Matthíasson SE; Stjernquist U; Ezban M; Ostergaard PB; Hedner U
Thromb Haemost; 1996 Apr; 75(4):585-9. PubMed ID: 8743183
[TBL] [Abstract][Full Text] [Related]
4. Recombinant full-length tissue factor pathway inhibitor (TFPI) prevents thrombus formation and rethrombosis after lysis in a rabbit model of jugular vein thrombosis.
Kaiser B; Fareed J
Thromb Haemost; 1996 Oct; 76(4):615-20. PubMed ID: 8903005
[TBL] [Abstract][Full Text] [Related]
5. Experimental studies on the antithrombotic and haemorrhagic effects of heparin and a low molecular weight heparin derivative.
Kaiser B; Hauptmann J; Markwardt F
Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):119-25. PubMed ID: 2459005
[TBL] [Abstract][Full Text] [Related]
6. Effect of low molecular weight fucoidan and low molecular weight heparin in a rabbit model of arterial thrombosis.
Durand E; Helley D; Al Haj Zen A; Dujols C; Bruneval P; Colliec-Jouault S; Fischer AM; Lafont A
J Vasc Res; 2008; 45(6):529-37. PubMed ID: 18463418
[TBL] [Abstract][Full Text] [Related]
7. Additive effect of the combined administration of low molecular weight heparin and recombinant hirudin on thrombus growth in a rabbit jugular vein thrombosis model.
Biemond BJ; Levi M; Nurmohamed MT; Büller HR; ten Cate JW
Thromb Haemost; 1994 Sep; 72(3):377-80. PubMed ID: 7855787
[TBL] [Abstract][Full Text] [Related]
8. The effect of taurolidine on experimental thrombus formation.
Kaptanoglu L; Kucuk HF; Colak E; Kurt N; Bingul SM; Akyol H; Torlak OA; Yazici F
Eur J Pharmacol; 2008 Jan; 578(2-3):238-41. PubMed ID: 17961549
[TBL] [Abstract][Full Text] [Related]
9. Antithrombotic properties of a truncated recombinant tissue factor pathway inhibitor in an experimental venous thrombosis model.
Holst J; Lindblad B; Bergqvist D; Nordfang O; Ostergaard PB; Petersen JL; Nielsen G; Hedner U
Haemostasis; 1993 Mar; 23 Suppl 1():112-7. PubMed ID: 8495862
[TBL] [Abstract][Full Text] [Related]
10. In vivo study of bleeding and antithrombotic effects of low molecular weight heparin ML-009723.
Malinowska K; Iqbal O; Hoppensteadt DA; Walenga JM; Fareed J
Semin Thromb Hemost; 1993; 19 Suppl 1():58-62. PubMed ID: 8395732
[No Abstract] [Full Text] [Related]
11. Nonpeptide factor Xa inhibitors III: effects of DPC423, an orally-active pyrazole antithrombotic agent, on arterial thrombosis in rabbits.
Wong PC; Crain EJ; Watson CA; Zaspel AM; Wright MR; Lam PY; Pinto DJ; Wexler RR; Knabb RM
J Pharmacol Exp Ther; 2002 Dec; 303(3):993-1000. PubMed ID: 12438519
[TBL] [Abstract][Full Text] [Related]
12. The correlation between plasma anti-factor Xa activity and haemostatic tests in healthy dogs, following the administration of a low molecular weight heparin.
Mischke R; Grebe S
Res Vet Sci; 2000 Dec; 69(3):241-7. PubMed ID: 11124095
[TBL] [Abstract][Full Text] [Related]
13. Antithrombotic efficacy of a recombinant nematode anticoagulant peptide (rNAP5) in canine models of thrombosis after single subcutaneous administration.
Rebello SS; Blank HS; Rote WE; Vlasuk GP; Lucchesi BR
J Pharmacol Exp Ther; 1997 Oct; 283(1):91-9. PubMed ID: 9336312
[TBL] [Abstract][Full Text] [Related]
14. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
Agnelli G; Pascucci C; Nenci GG; Mele A; Bürgi R; Heim J
Thromb Haemost; 1993 Aug; 70(2):294-300. PubMed ID: 8236138
[TBL] [Abstract][Full Text] [Related]
15. Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939)--an oral, direct factor Xa inhibitor.
Biemond BJ; Perzborn E; Friederich PW; Levi M; Buetehorn U; Büller HR
Thromb Haemost; 2007 Mar; 97(3):471-7. PubMed ID: 17334516
[TBL] [Abstract][Full Text] [Related]
16. A comparative study of the anticoagulant and anti-thrombotic effects of unfractionated heparin and a low molecular weight heparin (Fraxiparine) in an experimental model of human venous thrombosis.
Diquélou A; Dupouy D; Cariou R; Sakariassen KS; Boneu B; Cadroy Y
Thromb Haemost; 1995 Nov; 74(5):1286-92. PubMed ID: 8607111
[TBL] [Abstract][Full Text] [Related]
17. Antithrombotic efficacy of thrombin inhibitor L-374,087: intravenous activity in a primate model of venous thrombus extension and oral activity in a canine model of primary venous and coronary artery thrombosis.
Cook JJ; Gardell SJ; Holahan MA; Sitko GR; Stump GL; Wallace AA; Gilberto DB; Hare TR; Krueger JA; Dyer DL; Sanderson PE; Vacca JP; Shafer JA; Lynch JJ
J Pharmacol Exp Ther; 1999 Apr; 289(1):503-10. PubMed ID: 10087043
[TBL] [Abstract][Full Text] [Related]
18. [Inactivated factor VII exercises a powerful antithrombotic activity in an experimental model of recurrent arterial thrombosis].
Ragni M; Golino P; Cirillo P; Pascucci I; Scognamiglio A; Ravera A; Esposito N; Battaglia C; Guarino A; Chiariello M
Cardiologia; 1996 Jan; 41(1):51-8. PubMed ID: 8697470
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and delayed experimental anti-thrombotic effect of two domain non-glycosylated tissue factor pathway inhibitor.
Holst J; Lindblad B; Westerlund G; Bregengaard C; Ezban M; Ostergaard PB; Nordfang O; Hedner U
Thromb Res; 1996 Feb; 81(4):461-70. PubMed ID: 8907295
[TBL] [Abstract][Full Text] [Related]
20. Construction and functional evaluation of hirudin derivatives with low bleeding risk.
Zhang C; Yu A; Yuan B; Dong C; Yu H; Wang L; Wu C
Thromb Haemost; 2008 Feb; 99(2):324-30. PubMed ID: 18278181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
